Here are five observations:
1. The comparative evaluation study analyzed the improvement of new bone growth and reduction in infection rate after debridement in a rat osteomyelitis model. The study compared the use of CERAMENT|G to the use of CERAMENT|BONE VOID FILLER without antibiotics to the use of no void filler.
2. The CERAMENT|G exhibited no infection and greater new bone growth at six months, compared to the other two groups.
3. Mathias P. Bostrom, MD, HSS, said the study supports CERAMENT|G as available void filler for managing osteomyelitis.
4. CERAMENT|G received CE-mark in 2013 and is in the process of obtaining FDA clearance. It is the first antibiotic eluting bone substitute intended to protect bone healing in osteomyelitis management.
5. BONESUPPORT, headquartered in Lund, Sweden, develops injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation.
More articles on devices:
SeaSpine creates general counsel position: 5 things to know
Asia to see fastest growth in spinal implants & surgical devices market: 5 takeaways
Ellipse Technologies files $75M IPO: 4 takeaways
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
